This multicenter analysis included 301 oligometastatic NSCLC patients treated with pulmonary SBRT for 336 lung metastases. In routine clinical practice, SBRT for pulmonary oligometastatic NSCLC achieved favorable LC and promising OS. The dominant failure pattern was distant with a continuously high risk of disease progression for many years. Prospective studies should therefore combine local therapy with novel systemic treatments.
Wed Jun 26, 2019 03:00
Chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes.1 First and second generation ALK-TKIs (tyrosine kinase inhibitor) were developed and showed clinical response for ALK-rearranged NSCLC. 2-4 However, resistance to those ALK-TKIs almost develops, resulting in clinical relapse. 5, 6 Lorlatinib is a third generation ALK-TKI and has demonstrated significant antitumor...
Tue Jun 25, 2019 03:00
Immunotherapy is a recent therapeutic option that targets the patient’s self-tolerance against tumor cells. Following its successful use in metastatic melanoma, PD-1 and PD-1 ligand inhibitors have become a major therapeutic option in many tissue and hematologic malignancies. One such PD-1 inhibitor, nivolumab, is FDA approved for treatment in malignant melanoma, non-small cell lung carcinomas, head and neck squamous-cell carcinomas, gastric carcinomas, urothelial carcinomas, and solid tumors with...
Tue Jun 25, 2019 03:00
The prognostic value of baseline liver metastases (LMs) was evaluated in 569 patients with advanced/metastatic non-small cell lung cancer receiving the PD-L1 inhibitor durvalumab. LMs were an independent negative prognostic factor for survival and were associated with significantly lower objective response rates. However, PD-L1 as an independent factor predicted benefit from durvalumab.
Tue Jun 25, 2019 03:00
Malignant pleural mesothelioma (MPM) is an aggressive disease with a unique morphology and distribution. Due to its peculiar growth pattern, clinical staging is difficult. Quantitative assessment such as tumour volume (TV) was suggested as an alternative prognostic evaluation. In this paper we aimed to compare the prognostic role of TNM clinical staging to that of alternative staging approaches based on the use of two quantitative clinical parameters, TV and number of pleural sites (NPS), in MPM...
Tue Jun 25, 2019 03:00
There are no approved effective treatments in advanced non-small cell lung cancer (NSCLC) patients with exon 20 insertion epidermal growth factor receptor (EGFR) mutations. In the present survey of 3805 NSCLC patients screened for EGFR mutations, 84 patients had an exon 20 insertion. First-line pemetrexed-containing therapies were related to better outcomes. The mutation A763_Y764 insFQEA was related to a favorable response to tyrosine kinase inhibitors.
Tue Jun 25, 2019 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου